FDA Seeks Input on Biosimilar Product Development Guidance

Start
​​​​​​​On July 25, 2024, the FDA published a notice establishing a public docket for commenting to obtain information to assist the FDA in assessing how best to advance the development of new biosimilar products, as part of the Biosimilar Use Free Amendments of 2022 (“BsUFA III”)….
By: Goodwin
Previous Story

Dental Specialists Data Breach Affects an Estimated 38,442 People

Next Story

The Importance of Prong Two of Step 2A for AI inventions